How GLP-1s and RAGE control diabetic kidney damage
Data from Australian researchers could partly explain why a trial of a new drug for diabetes, was recently halted because it was found...
top of page
Browse by category
Search
New drug delivery system could reduce daily diabetes injections to three a year
Materials engineers at Stanford University have developed a novel hydrogel drug delivery system that transforms daily or weekly...
FDA approves Lilly's Zepbound (tirzepatide) for chronic weight management
The FDA has approved Eli Lilly and Company's Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that...
GLP-1/GIP candidate VK2735 shows reductions in subjects' liver fat content and plasma lipid levels
Outcomes from Viking Therapeutics’ Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735 were...
Browse by tag
bottom of page